After false start, Merck claims Keytruda approval in early breast cancerMerck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a Share XAfter false start, Merck claims Keytruda approval in early breast cancerhttps://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/
BMS pulls speedy Opdivo approval for liver cancer in USBristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for Share XBMS pulls speedy Opdivo approval for liver cancer in UShttps://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/
FDA okays Merck’s would-be Prevnar rival VaxneuvanceThe FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer Share XFDA okays Merck’s would-be Prevnar rival Vaxneuvancehttps://pharmaphorum.com/news/fda-okays-mercks-would-be-prevnar-rival-vaxneuvance/
Shot in the arm for Affinivax as it challenges Pfizer’s PrevnarAlready facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Share XShot in the arm for Affinivax as it challenges Pfizer’s Prevnarhttps://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/
Merck pulls Keytruda’s FDA nod for third-line stomach cancerMerck & Co will voluntarily withdraw a US marketing approval for cancer immunotherapy blockbuster Keytruda in gastric cancer, Share XMerck pulls Keytruda’s FDA nod for third-line stomach cancerhttps://pharmaphorum.com/news/merck-pulls-keytrudas-fda-nod-for-third-line-stomach-cancer/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
In a class first, Merck’s Keytruda extends survival in cervical cancerMerck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live Share XIn a class first, Merck’s Keytruda extends survival in cervical cancerhttps://pharmaphorum.com/news/in-a-class-first-mercks-keytruda-extends-survival-in-cervical-cancer/
AZ, MSD’s Koselugo is first EU therapy for neurofibromatosisThe European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share XAZ, MSD’s Koselugo is first EU therapy for neurofibromatosishttps://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
Merck nabs $1.2 billion order for oral COVID antiviral from USThe US government has placed an order with Merck & Co to buy 1.7 million courses of its Share XMerck nabs $1.2 billion order for oral COVID antiviral from UShttps://pharmaphorum.com/news/merck-grabs-1-2-billion-order-for-oral-covid-antiviral-from-us/
